NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Aldeyra Therapeutics, Inc. (ALDX) Stock Analysis

Aldeyra Therapeutics, Inc. (ALDX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ALDX

$0.67

−$0.06 (−8.72%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALDX with… →

ALDX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.74
Previous Close
$0.73
Day's Range
0.66–0.75
52-Week Range
0.65–5.93
Volume
595.77K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.20
Valuation
Market Cap
$40.44M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.38
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$33.85M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
60.33M
1-Year Return
−87.83%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.18M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ALDX closed at $0.67, −87.83% over 1 year.

Aldeyra Therapeutics, Inc. (ALDX) has a market capitalization of $40.44M.

In fiscal 2025, ALDX reported revenue of $0.00.

ALDX Stock Return by Calendar Year

Aldeyra Therapeutics, Inc. (ALDX) 10-year return: what $10,000 became

1 year
$10,000 $1,217
−87.83%
5 years
$10,000 $823
−91.77%
10 years
$10,000 $984
−90.16%

If you had invested $10,000 in Aldeyra Therapeutics, Inc. (ALDX) 10 years ago, at the close on October 21, 2016, it would have been worth $984 at the close on October 21, 2026: −90.16% in total, −20.69% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−87.06%
2025+3.81%
2024+42.17%
2023−49.57%
2022+74.00%
2021−41.69%
2020+18.07%
2019−30.00%
2018+22.06%
2017+27.10%
2016 (partial year)−9.01%

As of October 21, 2026.

ALDX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$33.85M—
2024$0.00−$55.85M—
2023$0.00−$37.54M—
2022$0.00−$62.02M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$35.27M−$33.85M—
2024$0.00—−$60.12M−$55.85M—
2023$0.00—−$42.79M−$37.54M—
2022$0.00—−$62.68M−$62.02M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Aldeyra Therapeutics, Inc. (ALDX) at $40.44M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 6 employees.

The most recent close on file for ALDX is $0.67, dated October 21, 2026. That is −$0.06 (−8.72%) against the previous close. Over the past 52 weeks the price has ranged from $0.65 to $5.93. The latest close sits 3.12% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $33.85M. Earnings per share on a trailing basis come to −0.38.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is −87.83%. Across 10 years the annualized return works out at −20.69%. The reported beta is 1.2. Daily returns over the trailing 10 years annualize to a volatility of 94.77%.

Growth & Income

No dividend is on file for ALDX.

Across the complete calendar years on file, 2022 returned +74.00% and 2023 returned −49.57%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the total return is −87.06% year to date.

Peer Comparison

Aldeyra Therapeutics, Inc. (ALDX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aldeyra Therapeutics, Inc. ALDX $40.44M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Aldeyra Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Visit website →